Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Immunovant Inc. Common Stock — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.68 (market cap $4.59B), while Immunovant Inc. Common Stock trades at $30.41 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Immunovant Inc. Common Stock for 0 Days on average.
| DFTX | IMVT | |
|---|---|---|
Market Cap | $4.59B | $6.25B |
Volume | 2,103,937 | 1,755,411 |
Sector | Health | Health |
52-Week High | $48.45 | $44.96 |
52-Week Low | $10.68 | $17.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.55B | $5.35B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
